Retrospective Analysis of the Intrathecal Morphine Pump Use after Insurance Benefits: Focused on Economic Efficiency by 김은경
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
경 지. 하는  저 물  개 , 형 또는 가공할 수 없습니다. 
１
의학석사 학위논문
Retrospective Analysis of the Intrathecal Morphine Pump Use 
after Insurance Benefits: Focused on Economic Efficiency
보험 급여 적용 후 척수강 내 모르핀 펌프에 대한 후향적 분석: 
경제적 효율성을 중심으로





A thesis of the Degree of Master of Philosophy
보험 급여 적용 후 척수강 내 모르핀 펌프에 대한 후향적 분석: 
경제적 효율성을 중심으로
Retrospective Analysis of the Intrathecal Morphine Pump Use 
after Insurance Benefits: Focused on Economic Efficiency
October 2017





Retrospective Analysis of the Intrathecal Morphine Pump Use 
after Insurance Benefits: Focused on Economic Efficiency
By
Eunkyoung Kim
A thesis submitted to the Department of Medicine in partial fulfillment of the 
requirements for the Degree of Master of Philosophy in Anesthesiology and Pain 
Medicine at Seoul National University College of Medicine
October 2017





보험 급여 적용 후 척수강 내 모르핀 펌프에 대한 후향적 분석: 
경제적 효율성을 중심으로
지도교수 김용철
이 논문을 의학석사 학위논문으로 제출함




김은경의 의학석사 학위논문을 인준함
2017 년 8 월
위  원  장  ______________________
부위원장  ______________________
위       원   ______________________
５
Abstract
Introduction: The aims of this study were to investigate the financial break-even point (FBEP)
and patients’ satisfaction in patients who received IntraThecal Morphine Pump (ITMP) 
implantation after the initiation of the Korean National Health Insurance (KNHI) reimbursement 
policy in Korea.
Method: We collected data through retrospective database analysis and direct phone calls to 
patients who underwent ITMP implantation at the Seoul National University Hospital (SNUH) 
Pain clinic between July 2014 and May 2016. Pain severity, changes in the Morphine Equivalent 
Daily Dosage (MEDD), any adverse events associated with ITMP implantation, and patients’ 
satisfaction were determined. In addition, we calculated the FBEP of ITMP in patients via 
investigating the patient's actual medical costs and insurance information.
Results: During the period, 23 patients received ITMP implantation at SNUH, and 20 patients 
were included in our study. An 11-point NRS pain scores were significantly reduced compared to 
the baseline value (P < 0.001). The median intrathecal MEDD before ITMP implantation was 
0.59 [IQR: 0.55-0.82]. Throughout the follow-up period, the total MEDD increased steadily to 
0.77 [IQR: 0.53-1.08] at 1 year which was 126% of baseline (P < 0.001). More than a half (60%) 
responded that the ITMP therapy was somewhat satisfying and 16 patients (80%) agreed that the 
ITMP helped to control their pain. The FBEP was 28 months for ITMP implantation treatment 
after the KNHI reimbursement policy.
６
Conclusions: In conclusion, ITMP provided effective chronic pain management with improved 
satisfaction and reasonable FBEP of 28 months with 50% financial coverage by KNHI program.
---------------------------------------------------------------------------------------------------------------------
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Introduction
Chronic pain is a major public health issue affecting 20% of the adult population worldwide [1-3]. The 
personal and socioeconomic effects of chronic pain are considered to be at least as great as those of other 
established healthcare priorities, including cardiovascular disease and cancer [4]. Although it impacts 
quality of life in multiple functional domains, including family life, workplace performance, social 
interactions, and sleep patterns [1, 2], less than 2% of chronic pain patients have access to a 
comprehensive specialist pain clinic [5, 6]. The Declaration of Montreal states that pain management is 
inadequate across most of the world (IASP, 2012). 
Patients with chronic, intractable pain may benefit from interventional strategies such as intrathecal 
morphine pump (ITMP) [2]. The intrathecal (IT) administration of opioid medications through ITMP
permits the delivery of higher drug concentrations into the cerebrospinal fluid with lower concentrations 
reaching the systemic circulation [7]. This direct action of analgesics at spinal receptors accompanied by 
reduced drug delivery to the brain via the blood-brain barrier may provide clinical benefits with lower 
risks of adverse effects compared to systemic opioid therapy [8, 9]. Therefore, although relegated to one 
of the interventions of ‘last resort’, ITMP should be considered to improve pain control, optimize patient 
functionality, and minimize the use of systemic pain medications in appropriately selected patients with 
refractory chronic pain [10].
Despite these advantages, the substantial costs that arise at the time of surgical implantation (US$
16,000 in Korea to US$ 35,000 in the USA) and difficulties with reimbursement continue to negatively 
affect ITMP use [11]. In Korea, the high cost of ITMP implantation is the main obstacle to its use-except 
in extremely rare cases. However, since July 2014, the Korean National Health Insurance (KNHI) 
program began financially supporting 50% of the ITMP implantation cost in select refractory chronic pain 
patients. Currently, Korean government reimbursement is approved for patients with the following 
conditions: long-term severe pain (persistent numerical rating scale [NRS] pain score ≥ 7), insufficient 
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pain control for 6 months when using other analgesic methods, patient life expectancy > 1 year, and 
cancer pain that is unresponsive to high doses of oral morphine or an equivalent dose of other narcotic 
analgesics. 
A previous study in eleven patients with non-cancer pain and one cancer patient that underwent ITMP
therapy in Korea indicated that the median time required to reach the financial break-even point (FBEP)
was 24.2 months [12]. The new KNHI reimbursement policy may promote wider use of ITMP as a 
treatment option for chronic pain patients in Korea, which would affect the FBEP in Korean patients.
Therefore, this study was performed to investigate the FBEP in patients receiving ITMP implantation 
since July 2014 after the initiation of the KNHI reimbursement policy and to assess patient satisfaction.
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Materials and Methods
This retrospective study was approved by the institutional review board (IRB) of Seoul National 
University Hospital (SNUH; IRB No. H-1601-053-733). Upon IRB approval, we identified patients that 
received ITMP implantation between July 2014 and May 2016 at the department of Anesthesiology and 
Pain Medicine of SNUH. We performed a retrospective database analysis that weighted the pre-
implantation and post-implantation claims for ITMP costs and surveyed patients by in-person phone calls 
to evaluate the average level of satisfaction after implantation. The requirement for written informed 
consent was waived by SNUH’s IRB.
Data was extracted from patients' electronic medical records, the operative reports, and the medical
progress notes. We included demographic and clinical characteristics of the patients such as age, gender, 
height, weight, pain duration, diagnosis, prior surgical history, and underlying diseases (diabetes mellitus 
and concomitant psychopathologies).
Pain severity using an 11-point NRS pain score was determined by a retrospective review of the patient’s 
electronic medical records before ITMP as a baseline score and for 1 year after ITMP implantation. 
Changes in the morphine equivalent daily dosage (MEDD) before and after ITMP implantation were also 
investigated, including all opioid medications administered orally, intrathecally, and/or transdermally. 
Escalation in daily opioid dosage was investigated over a 1-year period after ITMP implantation in each 
patient. In addition, concomitant around-the-clock and/or pro re nata analgesics other than strong opioids, 
including non-opioid/weak opioid analgesics such as tramadol, acetaminophen, and non-steroidal anti-
inflammatory drugs, were reviewed. Interventional procedures or conservative treatments other than 
analgesic medications for managing pain were also assessed. Any complications associated with the 
ITMP, including constipation, nausea, vomiting, urinary retention, dizziness, dry mouth, and diaphoresis, 
were thoroughly reviewed. The patients’ overall satisfaction following ITMP implantation was surveyed 
at one year via a phone call and rated on a five-point Likert scale from “extremely satisfied” to 
“extremely dissatisfied.” We then surveyed the patients regarding their overall recommendations to 
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improve the device.
Financial information was obtained from the data processing department (DPD) and insurance review 
department (IRD) of SNUH. In addition, the IRD provided data about each participant’s type of insurance 
coverage. Actual payments for the entire medical services for 6 months before ITMP implantation, 
consistent with the reimbursement policy of the KNHI program, and for one year after the implantation 
were calculated. Payments for medical services performed at facilities other than SNUH were not 
included in this study. Average medication costs (e.g., oral medication and patches) were investigated at 
three pharmacies close to SNUH.
The DPD provided the actual costs paid by each patient before, during, and after ITMP implantation, 
which included the costs for all medical services performed at SNUH. The total cost prior to ITMP 
implantation included the costs of medical services, interventions, procedures, and medications for 6 
months before ITMP implantation. The total cost after ITMP implantation included outpatient medical 
costs, analgesics for breakthrough pain, and ITMP refills for one year after the ITMP implantation. With 
regard to the total implantation cost, each patient’s actual payment for the ITMP implantation procedure, 
including hospitalization, was calculated. The total cost of medical services during the treatment period, 
expressed in Korean Won (KRW)/day, was divided into pre- and post-ITMP implantation segments to 
determine the FBEP. 
NRS pain scores and the daily costs before and after ITMP implantation were compared. Each patient’s 
total payment of medical costs for ITMP implantation divided by the difference between the costs per day 
before and after the ITMP implantation was used to define the FBEP. Difference between two time-points 
were analyzed using paired t-test or Wilcoxon signed rank test for continuous variables with a normal or 
non-normal distribution, respectively. Statistical analyses were performed using SPSS version 20.0 (IBM 
Corp., Armonk, NY). The data are expressed as median values [Interquartile range (IQR)]. In all analyses, 
P < 0.05 was taken to indicate statistical significance.
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Results
Twenty-three patients received ITMP implantation with a Medtronic SynchroMed II® pump (Medtronic, 
Inc., Minneapolis, MN) at SNUH between July 2014 and May 2016 (Figure 1). All surgical procedures 
for ITMP implantation were performed by one pain specialist (Y. C. K). Three patients were excluded 
from the study for the following reasons: one patient received ITMP implantation with baclofen, one
patient received a replacement ITMP following the first ITMP implantation in 2008, and one patient was 
mainly managed at another hospital and only visited SNUH for ITMP treatment. Therefore, 20 patients 
were included in the study. The demographic characteristics of the patients are shown in Table 1. All 
patients were implanted with ITMP for the management of chronic non-cancer pain. The most common 
diagnoses for ITMP therapy in patients with chronic non-cancer pain were complex regional pain 
syndrome (n = 7) and failed back surgery syndrome (n = 7), followed by fibromyalgia (n = 2), post-




*Thirteen patients that received 50% benefits from the new KNHI policy were included to calculate the 
financial break-even point. 
NHI = Korean national health insurance; MA = medical aid; WCP = worker’s compensation plans; CI = 
car insurance; and FBEP = financial break-even point.
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Table 1. Demographics
FBSS = failed back surgery syndrome; FM = fibromyalgia; PTPS = posttraumatic pain syndrome; CRPS = complex regional pain syndrome; 
KNHI = Korean national health insurance; MA = medical aid; WCP = worker’s compensation plans; CI = car insurance; y = year; mon = month;
and IQR = interquartile range
No. Gender Age (y) BMI (kg/m2)
Duration of pain
(month)
Diagnosis Baseline NRS pain score Insurance type
1 M 41 18.2 63 FBSS 10 KNHI
2 M 28 29.0 111 FM 10 KNHI
3 M 54 27.7 58 FBSS 8 KNHI
4 M 61 23.5 63 PTPS 9 KNHI
5 F 70 24.4 37 PTPS 10 KNHI
6 F 37 23.6 17 CRPS II 10 KNHI
7 M 59 25.5 71 FBSS 8 KNHI
8 M 76 25.8 187 PTPS 10 KNHI
9 M 75 26.0 63 FBSS 9 KNHI
10 F 74 21.3 195 FBSS 10 KNHI
11 F 44 20.7 38 CRPS I 10 MA
12 F 55 29.1 104 FBSS 10 MA
13 M 43 29.0 52 CRPS II 10 MA
14 M 53 26.1 86 CRPS I 9 WCP
15 M 52 25.8 81 CRPS I 9 CI
16 M 42 28.5 16 CRPS I 10 CI
17 M 31 41.8 46 CRPS II 10 CI
18 M 54 27.9 33 FM 9 CI
19 M 46 21.2 126 PTPS 9 WCP
20 M 47 25.2 24 FBSS 10 WCP
Median 53 25.8 63 10
(IQR) (43.0-60.0) (23.6-28.1) (38.0-91.0) (9.0-10.0)
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Figure 2 shows the changes in the 11-point NRS pain score between pre- and post-implantation. The 
baseline median NRS pain score was 10 and ranged between 8 and 10. The value decreased to within the 
range of 0 to 8 with a median score of 6 at 1 week; all patients (n = 20) responded that their pain had 
decreased by more than 2 of 10 points after ITMP implantation. Although the NRS pain score increased 
steadily for 1 year after ITMP implantation, the median NRS pain score was still reduced relative to the 
baseline at 12 months, with a median score of 5, ranging from 3 to 8. Eighteen patients (80%) still showed 
a reduction of ≥ 2 points in their NRS pain score at 1 year. The NRS pain scores at each follow-up point 
were significantly reduced compared to the baseline value before ITMP implantation (P < 0.001 between 
the baseline score and score at each follow-up point). 
The median IT MEDD before ITMP implantation was 0.59 [IQR: 0.55-0.82] (Figure 3). The median 
initial setting of IT dosage via ITMP was 0.47 mg/day [IQR: 0.44-0.65], which was 70–90% of the 
previous MEDD in each case at the discretion of the physician. In addition, patients received a concurrent 
immediate release form of opioid; therefore, the total MEDD at 1-week follow-up, calculated as IT 
administration was 0.61 [IQR: 0.46-0.82]. Throughout the follow-up period, the MEDD was increased 
steadily to 0.60 [IQR: 0.47-0.88] as IT administration via ITMP and 0.77 [IQR: 0.53-1.08] at 1 year as the 
total MEDD, representing a 126% of baseline (P < 0.001 for both IT and total administration). 
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Figure 2. Numeric rating scale (NRS) pain scores from pre-implantation to 12 months after implantation. 
The box plot shows a set of three quartiles and the maximum and minimum graphically. At Pre-ITMP and 
3 months, the maxima are not displayed because they were same as the median 3rd quartile and the 3rd 
quartile, respectively.
*Statistically significant difference between the time point and Pre-ITMP (P < 0.05). 
wk = week; and m = month
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Figure 3. Daily intrathecal morphine equivalent drug doses (MEDD) at various time points. The box plot 
shows a set of three quartiles and the maximum and minimum graphically. 
*Statistically significant difference between the initial total morphine dose and each time point (P < 0.05).
The total morphine dose is calculated by converting the amount of morphine entering the patient's 
intrathecal (IT) and all other routes into the amount of morphine entering the IT.
※Statistically significant difference between the total IT morphine dose as the initial setting and each time 
point (P < 0.05).
wk = week; and m = month
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The 20 patients included in the analysis were surveyed by an in-person phone call and asked about their 
overall satisfaction after the ITMP implantation treatment using a 5-point Likert scale. Twelve patients 
(60%) responded that it was somewhat satisfying, four patients (20%) responded that they were ‘neither 
satisfied nor dissatisfied’ with ITMP management, two patients (10%) were ‘completely dissatisfied’, and 
two patients refused to answer the question (Figure 4). Patients that were ‘completely dissatisfied’ also 
complained of severe worsening of pain accompanied by neuropsychiatric panic disorders such as panic or 
depressive disorders. Nonetheless, all patients agreed that the frequency and intensity of their pain had 
been alleviated. Sixteen patients (80%) also agreed that the ITMP helped to control pain. Finally, when we 
surveyed patients about their recommendations to improve the device, most patients (n = 16, 80%) 
suggested that a reduction in the pump reservoir size and the acquisition of a controlling device for self-
infusion (patient-controlled analgesia) would improve general satisfaction and pain control. A personal 
therapy manager (myPTM™; Medtronic, Inc.) was not available before November 2016 in South Korea.
２０
Figure 4. Overall satisfaction after intrathecal morphine pump (ITMP) implantation treatment using a 5-
point Likert scale. One year after the ITMP implantation, we interviewed twenty patients by phone call 
directly and asked for satisfaction with the ITMP therapy. Of the 18 patients who answered, twelve (60% 
out of 20 patients) responded ‘somewhat satisfied’, four (20%) answered ‘neither satisfied nor 
dissatisfied’, and two (10%) ‘completely dissatisfied’. None of the patients answered ‘somewhat 
dissatisfied’ and ‘completely satisfied’.
２１
Table 2. Adverse events observed after ITMP implantation. Adverse events 
between initial visit and after 12 months were not statistically significant.
There were no serious life-threatening side effects, and the number of people 
without side effects was 10 (50%) in the initial visit and 12 60%) in the after 
12 months.
Initial visit (%) After 12 months (%)
Dysuria 3 (15) 1 (5)
Nausea 2 (10) 1 (5)
Vomiting 1 (5) 0 (0)
Gastric discomfort 2 (10) 2 (10)
Constipation 2 (10) 1 (5)
Somnolence 2 (10) 0 (0)
Dizziness 1 (5) 1 (5)
Dry mouth 1 (5) 1 (5)
Skin eruption 0 (0) 0 (0)
２２
Itching 0 (0) 0 (0)
Anorexia 1 (5) 0 (0)
Edema 0 (0) 0 (0)
Sweating 0 (0) 1 (5)
Headache 0 (0) 0 (0)
No side-effects 10 (50) 12 (60)
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The side effects observed after ITMP implantation are shown in Table 2. At one week after ITMP 
implantation, half of the patients reported one or more adverse events associated with ITMP implantation; 
dysuria (n = 3) was the most frequent event, followed by nausea, vomiting, and gastric discomfort. Ten 
patients reported that they had not experienced any adverse events related to ITMP. At one year, twelve 
patients were free from opioid-related side effects.
To calculate the FBEP, we investigated each patient’s reimbursement insurance status (shown in Table 
1). Among the 20 patients in this study, 10 (50%) were reimbursed by KNHI coverage. Three patients 
(15%) were under Medical Aid (MA) as an extension of the KNHI program for minorities. Among the 
remainder, three patients were covered by Worker’s Compensation Plan Insurance (WCPI) and four 
patients were under Car Insurance (CI) coverage. KNHI paid 50% of ITMP costs and MA covered 50% of 
ITMP costs and partial professional fees. WCPI and CI covered 100% of ITMP costs. The actual total 
ITMP cost of the patient’s share of medical costs differed markedly according to the type of insurance, and 
ranged from 0 to 8580000 KRW. Therefore, to estimate the FBEP, we included only thirteen patients in the 
study who paid for 50% of their actual ITMP costs; ten were covered by KNHI and three had MA 
coverage. Their FBEP are shown in Table 3. Their pre-implantation medical costs ranged between 6011 
and 41129 KRW/day (median: 10905 KRW/day). The post-implantation medical cost per day ranged 
between 902 and 11178 KRW/day (median: 3461 KRW/day). It has been shown that the cost of medical 
care per day after ITMP implantation is significantly lower than the cost per day before implantation (P <
0.001). Our data show that a period of 28 months was required to reach the FBEP following ITMP 
implantation treatment.
２４
Table 3. Analysis of the cost effectiveness of ITMP treatment
*The cost actually paid for ITMP implantation under Korean national health insurance coverage.
**The cost paid for pain management per day.
†Difference in the pain management cost per day between before and after ITMP implantation.
††The cost of conventional medical management exceeded that of intrathecal drug pump therapy within the period expressed as the financial break-
even point.
ITMP = intrathecal morphine pump; FBEP = financial break-even point; KRW = Korean Won; KRW/d = Korean Won per day; mon = month; and 







(mon)Cost (KRW) KRW/d** Cost (KRW) KRW/d**
1 7,960,000 1,250,000 19,531 600,000 1,863 17,668 15
2 7,910,000 2,170,000 10,905 2,320,000 6,535 4,369 60
3 8,080,000 1,290,000 7,544 1,540,000 3,461 4,083 66
4 7,990,000 1,100,000 6,011 1,360,000 3,170 2,841 92
5 8,080,000 950,000 38,000 2,170,000 6,382 31,618 8
6 8,580,000 3,340,000 21,274 4,270,000 11,178 10,096 28
7 8,000,000 2,150,000 12,356 1,220,000 3,089 9,268 27
8 8,050,000 820,000 9,213 830,000 2,594 6,620 40
9 7,950,000 980,000 15,806 2,360,000 6,592 9,214 28
10 8,190,000 1,990,000 10,000 1,510,000 3,963 6,037 45
11 7,810,000 1,840,000 10,337 1,810,000 5,142 5,195 50
12 7,610,000 5,100,000 41,129 970,000 2,803 38,326 6
13 5,260,000 1,170,000 10,636 350,000 902 9,734 18
Median 7,990,000 1,290,000 10,905 1,510,000 3,461 9,214 28
(IQR) (7,910,000-8,080,000) (1,100,000-2,150,000) (10,000-19,531) (970,000-2,170,000) (2,803-6,382) (5,195-10,096) (18-50)
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Discussion
Chronic pain is acknowledged as a condition in its own right that results in both physical and 
emotional burdens on patients as well as a huge financial cost to society (currently estimated at 
more than €200 billion per annum in Europe and $150 billion per annum in the USA) [13].
Economic and reimbursement difficulties continue to constrain the use of advanced therapies
such as ITMP implantation for chronic pain patients [14]. Studies evaluating the cost-
effectiveness of ITMP implantation may encourage organizations to reduce costs or to increase 
health insurance coverage, and it may promote the use of this expensive therapy. Therefore, we 
performed a retrospective study to analyze the influence of Korea’s reimbursement policy, 
adopted in 2014, with regard to the FBEP for ITMP in chronic non-cancer pain patients at SNUH, 
trends in patient access to this treatment, and patients’ overall satisfaction.
With regard to the efficacy of ITMP, 80% (n = 18) of the patients in our study showed a 
reduction of ≥ 2 points in their NRS pain score at 1 year after ITMP implantation, and the other 
two patients showed a decrease of 1 point in their NRS pain score compared to the pre-
implantation score. Although the results of previous studies were contradictory with regard to the 
efficacy of ITMP use in chronic non-cancer and cancer pain patients, recent research by Hamza et 
al. strengthened the positive results reported for ITMP treatment (94% of non-malignant pain 
patients showed > 26% improvement in their pain score compared with the baseline) [15]. In our 
study, we also found a reduction in NRS pain score at the initial and final follow-up visits 
compared to the baseline score before ITMP implantation. We suggest that appropriate patient 
selection is the key to a successful outcome following ITMP treatment [16].
Increasing IT opioid administration, which was reported in previous studies, indicates that 
dose escalation may be independent of the opioid delivery method over the long term [17-20]. In 
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our study, the MEDD escalation was statistically significant, and researchers generally describe 
the escalation in MEDD to achieve the same analgesic effect as drug tolerance. Several articles 
have attempted to explain the mechanism of this phenomenon, and one author has argued that 
technical problems with ITMP could cause tolerance [16, 21]. Some authors have attempted to 
predict the occurrence of this resistance and have identified diagnosis, individual genotypes, and 
other factors as predictors of opioid dose escalation [22]. It has been shown that the biological 
characteristics of individuals determine the mechanism of pain generation, symptoms, and 
responses to drugs [23], and we anticipate that the development of these genetic studies will 
reduce treatment failures by individualized treatment.
In this study, the increase in median IT dosage was 126% at the first year of follow-up 
compared to the initial IT dosage. This rate of increase was relatively low compared to those 
suggested in a systematic review by Turner et al., which indicated a 2.6-7.4-fold increase in IT 
opioid dosage from initial levels at 24 months [17]. However, this was similar to the results of 
our previous study performed at the same hospital indicating that the IT dose escalation was 
136.9% during the first year [12]. We assume that a lower initial IT dose may have been related 
to the decreased IT escalation rate in our study, which may support previous studies suggesting 
that using a low-dose IT opioid trailing method had clinical benefit as an effective dosing strategy
[24, 25].  
With regard to satisfaction with ITMP treatment, 63% of patients were ‘somewhat satisfied’
with their ITMP therapy. This was an improvement in comparison with our previous study that 
showed that only 41% of patients were ‘somewhat satisfied’ prior to KNHI reimbursement [12]. 
Although, 20% of the patients in our study responded that they were ‘neither satisfied nor 
dissatisfied’ and 10% did not respond, all patients agreed that the frequency and intensity of their 
pain had been decreased and eased. The large size of the pump was one of the main issues to be 
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addressed in the future. Patients generally felt uncomfortable with the pump device when wearing 
thin clothes, while lying down, or sitting straight. Therefore, future ITMP development should 
include reducing the size of the device.
Prior to July 2014, Korean patients were required to pay all costs related to ITMP implantation 
with their own money. However, since the Korean reimbursement system was announced in July 
2014, 50% of ITMP costs can be reimbursed to patients that fulfill the established criteria of the 
KNHI program. This implies a huge economic benefit to patients considering ITMP treatment; 
however, there may be concerns about the inappropriate application of ITMP treatment. In the 
present study, when patients paid their medical costs using KNHI coverage, it took 28 months to 
obtain a financial advantage. Although this is somewhat longer than the period of 24.2 months 
that we reported in a previous study without KNHI coverage [12], it is still worthwhile when 
taking into account that the median longevity of patients with ITMP use is 5.4 years (95% 
confidence interval: 5.0–5.8) [2]. Studies in the USA have reported cost-effectiveness data for 
ITMP treatment, with a diverse range from 7.6 months in cancer patients to 22 months for 
patients with non-malignant pain [26]. As we did not administer the concept of quality-adjusted 
life years in our analysis of cost effectiveness and did not include costs paid to other hospitals, it 
is not possible to compare our results with previous cost-effectiveness data. However, when we 
consider that the overall medical service fee is much cheaper in Korea than in the USA and if we 
reflect on the benefits from the improvement in quality of life, the FBEP of 28 months in our 
study is not excessive. 
In South Korea with the new insurance policy, a wider range of patients gained access to 
ITMP therapy. According to the data provided by Medtronic, Inc., 109 ITMP implants were 
performed for two years after the introduction of the insurance system (2014-2016), but only 81 
ITMP implants were performed during the six years prior to the introduction of the insurance
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(2008 – 2014). In a previous study, 12 of 19 patients who were treated for 6 years between 2008
and 2014 were analyzed for cost [12], and this study was performed for 13 of 23 patients who 
were treated for two years between 2014 and 2016 . There was no difference in the survey 
method between the two papers. Patients who meet the KNHI-declared criteria are more likely to 
receive ITMP transplants than before, and the patients’ median economic break-even point for 
ITMP therapy has been lengthened despite insurance coverage. However, the statistically 
significant decrease in post-ITMP cost per day suggests that ITMP therapy has an economic 
benefit to the patient. In addition, the fact that the FBEP is shorter than the longevity of the pump 
can lead to the conclusion that if the patient maintains ITMP therapy for longer than the longevity 
of the pump, then ITMP therapy is more economical for the patient than conventional medical 
therapy. And a significant reduction in Post-NRS pain score can be interpreted as ITMP treatment 
contributing to the patient's effective pain reduction.
Since our study is a retrospective analysis, there is no control. However, the patients we 
analyzed were chronic pain patients with a median value of more than 5 years. In these chronic 
pain patients, the pain rarely disappears spontaneously. We performed the epidural morphine test 
before permanent insertion for the success of the ITMP procedure, and performed the ITMP 
permanent implant only if the effect was confirmed and the patient agreed. Therefore, regression 
to the mean bias can be ruled out.
There are several limitations to this study. First, this was a retrospective study, and our results 
may have been affected by characteristic confounders, including bias and variability in the 
quality of available information. Second, as mentioned previously, the concept of improvement in 
quality of life was not administered in our analysis. Furthermore, we did not include 
pharmaceutical and non-pharmaceutical treatment costs at other institutions. These may reduce 
the time needed for the FBEP, which was suggested in this study as 28 months. Finally, this was a 
２９
single-center study with a limited number of patients, which would result in several biases related 
to patient selection for ITMP treatment or medical costs other than ITMP treatment. Future 
prospective large cohort studies should attempt to validate the cost effectiveness of ITMP 
therapy.
In conclusion, ITMP provided effective chronic pain management with overall improved 
satisfaction and fewer systemic adverse events in our study. The FBEP was 28 months in patients 
with 50% coverage of their medical cost for ITMP implantation by the KNHI program. When we, 
as pain physicians, consider the application of ITMP therapy for the management of intractable 
chronic cancer or non-cancer pain, attention should be paid to appropriate patient selection as 
well as their clinical improvement and economic benefits. Additional studies are required to 
improve patients’ pain and analyze the cost effectiveness of ITMP management.
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국문 초록
서론: 본 연구의 목적은 한국의 척수강 내 모르핀 펌프 이식술을 받는 환자에 대한 국민 건강
보험 정책 시작 후 척수강 내 모르핀 펌프 이식을 받은 환자들의 재정적 손익 분기점과 환자
만족도를 조사하는 것이다. 
방법: 2014년 7월에서 2016년 5월 사이에 서울대학교병원 통증 클리닉에서 척수강 내 모르핀
펌프 이식을 받은 환자들을 대상으로 후향적인 의무기록 분석과 개별 전화 통화를 통해 통증의
강도, 모르핀의 등가 1일 용량의 변화, 척수강 내 모르핀 펌프 이식과 관련된 부작용 및 환자
만족도에 대한 자료를 수집했다. 또한 환자의 실제 의료 비용 및 보험 정보를 조사하여 척수강
내 모르핀 펌프의 재정적 손익 분기점을 계산하였다. 
결과: 해당 기간 동안 서울대학교병원에서 23명의 환자가 척수강 내 모르핀 펌프 이식을 받았고
20명의 환자가 본 연구에 포함되었다. 숫자 통증척도는 기준치와 비교하여 유의하게
감소하였고 (P < 0.001), 척수강 내 모르핀 펌프 이식 전의 모르핀 등가 1일 용량의 중앙값은
0.59였다 [IQR: 0.55-0.82]. 1년간의 추적 관찰 기간 동안 총 모르핀 등가 1일 용량은 기준선의
126%까지 지속적으로 증가하였다 (P < 0.001). 60%의 환자가 척수강 내 모르핀 펌프 이식에
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대해 다소 만족한다고 응답했으며 80%의 환자는 척수강 내 모르핀 펌프 이식이 통증조절에
도움이 된다고 응답하였다. 척수강 내 모르핀 펌프에 대한 재정적 손익분기점은 28개월로
조사되었다. 
결론: 척수강 내 모르핀 펌프는 효과적인 만성통증 관리를 제공하여 국민 건강 보험 정책에
의한 50%의 재정적 보상으로 28개월이라는 합리적인 재정적 손익분기점 및 환자 만족도의
개선을 이끌어냈다.
--------------------------------------------------------------------------------------------------------
주요어: 만성통증; 손익분기점; 척수강 내 펌프; 모르핀등가1일용량; 보험정책; 환자만족도




Abbreviation, Tables, and Figures
CI    car insurance
CRPS    complex regional pain syndrome
DPD    data processing department
FBEP    financial break-even point
FBSS    failed back surgery syndrome
FM    fibromyalgia
IASP    International Association for the Study of Pain
IBM    International Business Machines Corporation
IQR    interquartile range
IRB    institutional review board
IRD    insurance review department
IT    intrathecal
ITMP    intrathecal morphine pump
KNHI    Korean national health insurance
KRW    Korean Won
MA    medical aid
MEDD   morphine equivalent daily dosage
Mon       month
NRS    numerical rating scale
NY    New York
PTPS    posttraumatic pain syndrome
SNUH    Seoul National University Hospital
USA    United States of America
WCP    worker’s compensation plans
